Clinical Trials Browser

Phase 1/2 × Immune Checkpoint Inhibitors × 1 year × Clear all

NCT06502691 2026-03-02

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT06710847 2026-02-02

SYLVER

Phase 1/2 Active not recruiting

GastrointestinalGynecologic

Turcot syndrome, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07282184 2025-12-18

Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05013450 2025-12-17

Dupilumab_Metastatic NSCLC

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04631601 2025-10-07

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 1/2 Terminated

Bites and Stings

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03425279 2025-09-23

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

Phase 1/2 Completed

Neoplasms, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT05806385 2025-09-09

LOGIC

Phase 1/2 Not yet recruiting

Triple Negative Breast Neoplasms